Vivimed Labs Peer Comparison
NSE: VIVIMEDLAB | BSE: 532660
₹5.68
₹0.10
(1.79%)
As on 21-Sep-2026 10:27IST
Market cap
₹48 Cr
Revenue (TTM)
₹70 Cr
P/E Ratio
--
P/B Ratio
-0.2
Div. Yield
0 %
Edit
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
48 | 33,911 | 29,031 | 28,149 | 27,692 |
Revenue (₹ Cr) |
70 | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
-176.47 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
-231.21 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
-- | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
-- | 82.91 | 100.73 | 72.88 | -- |
Price-To-Book |
-0.19 | 6.74 | 21.63 | 16.31 | 3.46 |
Income Statement (₹ Cr)
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
69.99 | 3,564.00 | 1,935.80 | 1,461.80 | 9,205.28 |
|
Total Income
|
76.33 | 3,686.00 | 1,948.58 | 1,489.25 | 9,449.59 |
|
Total Expenditure
|
222.43 | 2,792.00 | 1,485.56 | 919.25 | 8,195.15 |
|
EBITDA
|
-152.44 | 772.00 | 450.24 | 542.56 | 1,010.13 |
|
Depreciation
|
26.05 | 226.00 | 50.83 | 37.68 | 857.51 |
|
EBIT
|
-178.49 | 546.00 | 399.41 | 504.88 | 152.62 |
|
Interest
|
4.18 | 217.00 | 40.84 | 3.77 | 342.73 |
|
Other Income
|
6.34 | 122.00 | 12.78 | 27.45 | 244.31 |
|
Exceptional Items
|
0.00 | 12.00 | 0.00 | 0.00 | -216.88 |
|
Profit before Tax
|
-176.33 | 463.00 | 371.35 | 528.56 | -162.68 |
|
Provision for Tax
|
0.14 | 49.00 | 83.14 | 141.21 | 209.13 |
|
Profit after Tax
|
-176.47 | 414.00 | 288.22 | 387.35 | -371.81 |
Liabilities (₹ Cr)
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-210.55 | 4,940.00 | 1,288.82 | 1,653.56 | 8,162.62 |
|
Minority Interest
|
0.00 | -5.00 | 0.00 | -1.13 | 0.00 |
|
Non-Current Liabilities
|
515.92 | 1,712.00 | 202.03 | 42.40 | 5,044.14 |
|
Current Liabilities
|
448.11 | 1,622.00 | 835.87 | 230.82 | 4,758.28 |
|
Total Liabilities
|
920.85 | 8,100.00 | 1,451.43 | 1,549.26 | 15,513.53 |
Assets (₹ Cr)
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
583.95 | 5,343.00 | 519.60 | 1,026.85 | 10,211.52 |
|
Current Assets
|
168.00 | 2,606.00 | 1,681.81 | 881.27 | 7,191.66 |
|
Total Assets
|
920.85 | 8,100.00 | 1,451.43 | 1,549.26 | 15,513.53 |
|
Total Debt*
|
376.33 | 1,859.00 | 393.17 | 8.18 | 4,720.27 |
|
Net Current Assets
|
-280.11 | 984.00 | 845.94 | 650.46 | 2,433.38 |
|
Contingent Liabilities
|
182.90 | 770.26 | 12.25 | 15.38 | 99.76 |
Cashflow (₹ Cr)
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.75 | -22.00 | 159.18 | 118.34 | 892.30 |
|
Cash Flow from Investing Activities
|
-4.53 | -783.00 | -64.81 | -223.94 | -477.46 |
|
Cash from Financing Activities
|
4.96 | 409.00 | -39.81 | 261.12 | -440.83 |
|
Net Cash Inflow / Outflow
|
-1.32 | -396.00 | 54.56 | 155.52 | -25.99 |
Ratios
Profitability Ratios
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-9.07 | 4.07 | 26.97 | 20.14 | 6.61 |
|
ROE (%)
|
0.00 | 8.38 | 29.77 | 25.18 | -3.85 |
|
ROA (%)
|
-21.08 | 4.94 | 24.77 | 21.93 | -2.21 |
|
EBIT Margin (%)
|
-255.02 | 15.32 | 20.63 | 34.54 | 1.66 |
|
Net Margin (%)
|
-231.21 | 11.23 | 14.79 | 26.01 | -3.93 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-39.80 | 18.37 | 46.65 | 40.90 | 0.78 |
|
EBIT Growth (%)
|
-436.45 | 252.26 | 62.13 | 124.50 | -70.53 |
|
Net Profit Growth (%)
|
-452.15 | 377.85 | 89.49 | 104.15 | -1,383.43 |
|
EPS Growth (%)
|
-452.15 | 1,001.33 | 78.60 | 42.32 | -484.84 |
|
Book Value Growth (%)
|
-68.36 | 29.77 | 42.49 | 94.96 | 2.28 |
Valuation Ratios
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.27 | 85.10 | 99.18 | 72.88 | -88.50 |
|
Price / Book Value
|
-0.19 | 6.74 | 21.63 | 16.31 | 3.46 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.09 | 0.07 | 0.00 |
|
EV/EBITDA
|
-2.78 | 45.82 | 64.29 | 51.52 | 31.51 |
|
Market Cap (₹ Cr)
|
0.00 | 23,064.69 | 0.00 | 19,988.69 | 29,731.27 |
Solvency Ratios
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-0.34 | 0.31 | 0.11 | 0.01 | 0.53 |
|
Short term debt to equity ratio
|
-8.89 | 0.11 | 0.54 | 0.02 | 0.12 |
|
Current Ratio
|
0.37 | 1.61 | 2.01 | 3.82 | 1.51 |
|
Quick Ratio
|
0.35 | 1.06 | 1.14 | 2.82 | 0.87 |
|
Interest Coverage
|
-41.16 | 3.13 | 10.09 | 141.16 | 0.53 |
Operating Efficiency Ratios
| Vivimed Labs | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
64.77 | 16.50 | 26.28 | 24.80 | 23.44 |
|
Asset Turnover
|
0.08 | 0.43 | 1.66 | 0.83 | 0.55 |
|
Receivable days
|
246.32 | 60.36 | 47.59 | 90.06 | 77.05 |
|
Inventory Days
|
192.78 | 64.42 | 62.58 | 61.02 | 77.13 |
|
Payable days
|
254.58 | 218.94 | 228.78 | 96.06 | 173.49 |
|
Cash Conversion Cycle
|
184.52 | -94.15 | -118.62 | 55.02 | -19.30 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
